3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
2
Unknown
1
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Neoplasms
4
Prostatic Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Substance-Related Disorders
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Interventions
Imatinib Mesylate
86
nilotinib
59
fludarabine phosphate
46
Cyclophosphamide
45
Mycophenolic Acid
37
Whole-Body Irradiation
35
Dasatinib
32
fludarabine
31
Tacrolimus
29
Cyclosporine
24
Busulfan
23
Peripheral Blood Stem Cell Transplantation
22
Methotrexate
20
bosutinib
18
Cytarabine
18
Granulocyte Colony-Stimulating Factor
16
Filgrastim
16
Melphalan
14
thymoglobulin
13
Antilymphocyte Serum
13
Stem Cell Transplantation
12
sargramostim
11
Thiotepa
11
Interferon-alpha
10
Cord Blood Stem Cell Transplantation
9
asciminib
8
Cyclosporins
8
ponatinib
7
Sirolimus
7
Radiotherapy
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Patient Reported Outcome Measures
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled